Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in Japanese Subjects With RRMS
NCT01440101Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2010
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Nov 2010; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01440101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440101.